logo
Plus   Neg
Share
Email

Stock Alert: Applied DNA Sciences Jumps 30% After Getting EUA For Covid-19 Testing Kit

Shares of Applied DNA Sciences, Inc. (APDN) are currently gaining over 30% on Friday morning after the U.S. FDA approved Emergency Use Authorization for expanded used of its COVID-19 testing kit.

APDN is currently trading at $11.56, up $2.85 or 32.72%, on the Nasdaq.

Applied DNA Sciences said FDA granted an Emergency Use Authorization amendment that both expands the installed base of PCR equipment platforms that can process the company's LineaTM COVID-19 Assay Kit and introduces automation to significantly increase the throughput of the assay by use of robotic RNA extraction.

The EUA amendment extends the RT-PCR platform authorization from the Applied Biosystems QuantStudio Dx to include Applied Biosystems' QuantStudio 5 Real-Time PCR system.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT